# Post Holdings, Inc.: Form 10-Q for the period ended Mar 31, 2017

- Company: [Post Holdings, Inc.](/companies/post.md) (CIK 1530950)
- Form: 10-Q
- Filed: 2017-05-09
- Accepted by EDGAR: May 9, 2017, 15:28 ET
- Period: 2017-03-31
- Accession: 0001530950-17-000097
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1530950/000153095017000097/post-33117x10xq.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1530950/000153095017000097/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2017-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 6 months, 2016-10-01 to 2017-03-31 | $2.51bn | us-gaap:SalesRevenueGoodsNet |
| Cost of revenue | 3 months, 2017-01-01 to 2017-03-31 | $891.3m | us-gaap:CostOfGoodsSold |
| Cost of revenue | 6 months, 2016-10-01 to 2017-03-31 | $1.76bn | us-gaap:CostOfGoodsSold |
| Gross profit | 3 months, 2017-01-01 to 2017-03-31 | $364.1m | us-gaap:GrossProfit |
| Gross profit | 6 months, 2016-10-01 to 2017-03-31 | $743.3m | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months, 2017-01-01 to 2017-03-31 | $187.3m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months, 2016-10-01 to 2017-03-31 | $451.4m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2017-01-01 to 2017-03-31 | $137.5m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2016-10-01 to 2017-03-31 | $213.7m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2017-01-01 to 2017-03-31 | $80.2m | us-gaap:InterestExpense |
| Interest expense | 6 months, 2016-10-01 to 2017-03-31 | $153.1m | us-gaap:InterestExpense |
| Income tax | 3 months, 2017-01-01 to 2017-03-31 | −$200.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2016-10-01 to 2017-03-31 | $50.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2017-01-01 to 2017-03-31 | −$4.0m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2016-10-01 to 2017-03-31 | $93.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2017-01-01 to 2017-03-31 | −$0.11 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2016-10-01 to 2017-03-31 | $1.18 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2017-01-01 to 2017-03-31 | −$0.11 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2016-10-01 to 2017-03-31 | $1.26 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2017-01-01 to 2017-03-31 | 68,200,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2016-10-01 to 2017-03-31 | 79,300,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2016-10-01 to 2017-03-31 | −$26.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2016-10-01 to 2017-03-31 | $63.9m | us-gaap:PaymentsToAcquireProductiveAssets |
| Dividends paid | 6 months, 2016-10-01 to 2017-03-31 | $6.8m | us-gaap:PaymentsOfDividends |
| Share repurchases | 6 months, 2016-10-01 to 2017-03-31 | $133.1m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2017-03-31 | $1.48bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2017-03-31 | $2.53bn | us-gaap:AssetsCurrent |
| Total assets | at 2017-03-31 | $9.83bn | us-gaap:Assets |
| Current liabilities | at 2017-03-31 | $456.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2017-03-31 | $6.84bn | us-gaap:Liabilities |
| Long-term debt | at 2017-03-31 | $5.27bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2017-03-31 | $4.5m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2017-03-31 | $2.99bn | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 41,520 characters.

The following discussion summarizes the significant factors affecting the consolidated operating results, financial condition, liquidity and capital resources of Post Holdings, Inc. This discussion should be read in conjunction with our unaudited condensed consolidated financial statements and notes thereto of Post Holdings, Inc. included herein and our audited Annual Report on Form 10-K for the fiscal year ended September 30, 2016. The terms “our,” “we,” “us,” “Company” and “Post” as used herein refer to Post Holdings, Inc. and its consolidated subsidiaries. Please note these discussions are subject to discussion under “Cautionary Statements Regarding Forward-Looking Statements” included below.

### OVERVIEW

We are a consumer packaged goods holding company operating in four reportable segments: Post Consumer Brands, Michael Foods Group, Active Nutrition and Private Brands. Our products are sold through a variety of channels such as grocery, club and drug stores, mass merchandisers, foodservice, ingredient and via the internet.

### Acquisitions & Divestitures

We completed the following acquisitions in fiscal 2017 and 2016:

- National Pasteurized Eggs, Inc. (“NPE”), acquired October 3, 2016; and
- Willamette Egg Farms (“WEF”), acquired October 3, 2015.

We completed the following divestiture in fiscal 2016:

- Certain assets of our Michael Foods Canadian egg business, sold March 1, 2016.

### RESULTS OF OPERATIONS

*dollars in millions*

|  | Three Months Ended March 31, 2017 | 2016 | favorable/(unfavorable) $ Change | % Change | Six Months Ended March 31, 2017 | 2016 | favorable/(unfavorable) $ Change | % Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Net Sales | $1,255.4 | $1,271.1 | $(15.7) | (1)% | $2,505.2 | $2,519.9 | $(14.7) | (1)% |
| Operating Profit | $137.5 | $162.5 | $(25.0) | (15)% | $213.7 | $295.4 | $(81.7) | (28)% |
| Interest expense, net | 80.2 | 77.2 | (3.0) | (4)% | 153.1 | 155.0 | 1.9 | 1% |
| Loss on extinguishment of debt | 62.5 | — | (62.5) | n/a | 62.5 | — | (62.5) | n/a |
| Other (income) expense | (1.0) | 90.9 | 91.9 | 101% | (145.5) | 106.8 | 252.3 | 236% |
| Income tax (benefit) expense | (0.2) | (10.5) | (10.3) | (98)% | 50.0 | 3.2 | (46.8) | (1,463)% |
| Net (Loss) Earnings | $(4.0) | $4.9 | $(8.9) | (182)% | $93.6 | $30.4 | $63.2 | 208% |

### Net Sales

Net sales decreased $15.7 million, or 1%, during the three months ended March 31, 2017, and decreased $14.7 million, or 1%, during the six months ended March 31, 2017, compared to the corresponding periods in the prior year. These decreases were primarily due to reduced net sales in our egg, cheese, pasta, and dried fruit and nut products, as well as the absence of net sales in the current year attributable to our Michael Foods Canadian egg business which was sold in fiscal 2016. Net sales in our ready-to-eat (“RTE”) cereal business were also down in the three months ended March 31, 2017. The net sales decreases were partially offset by the inclusion of incremental contribution from the current year acquisition of NPE and net sales growth in our *Premier Protein* ready-to-drink (“RTD”) shake and protein bar products, along with potato and peanut butter. For further discussion, refer to “Segment Results” within this section.

### Operating Profit

Operating profit decreased $25.0 million, or 15%, during the three months ended March 31, 2017, and decreased $81.7 million, or 28%, during the six months ended March 31, 2017. These decreases were primarily due to lower segment profit within our Michael Foods Group segment partially offset by segment profit growth within our Post Consumer Brands and Active Nutrition segments for both the three and six months ended March 31, 2017. Segment profit within our Private Brands segment increased in the three month period ended March 31, 2017. Operating profit was significantly impacted in the six months ended March 31, 2017 by a provision for legal settlement of $74.5 million in the Michael Foods Group, recorded in the first quarter of fiscal 2017. In addition, general corporate expenses and other were lower in the six months ended March 31, 2017. For further discussion, refer to “Segment Results” within this section.

### Interest Expense, Net

Interest expense increased $3.0 million, or 4%, during the three months ended March 31, 2017 compared to the corresponding period in the prior year. The increase was primarily due to an increase in the outstanding amount of debt principal driven by our August 2016 and February 2017 senior notes issuances, partially offset by a decrease in our weighted-average interest rate resulting from partial debt refinancings completed in the fourth quarter of fiscal 2016 and the second quarter of fiscal 2017. Interest expense decreased $1.9 million, or 1%, during the six months ended March 31, 2017, compared to the corresponding period in the prior year, primarily due to a decrease in our weighted-average interest rate. Our weighted-average interest rate on our total outstanding debt was 6.0% and 6.9% at March 31, 2017 and 2016, respectively. For additional information on our debt, refer to Note 14 within the Notes to Condensed Consolidated Financial Statements and Quantitative and Qualitative Disclosures About Market Risk within Item 3.

### Loss on Extinguishment of Debt

During the three and six months ended March 31, 2017, we recognized a loss of $62.5 million related to the extinguishment of debt. The loss related to the extinguishment of the remaining portion of our 7.375% senior notes and the entire principal balance of our 6.75% senior notes. The expense included a tender premium of $67.9 million and deferred financing fee write-offs of $10.1 million, partially offset by $15.5 million of write-offs for unamortized debt premium. No such losses were incurred in the prior year periods. For additional information on our debt, refer to Note 14 in the “Notes to Consolidated Financial Statements.”

### Other (Income) Expense

During the three and six months ended March 31, 2017, we recognized net gains of $1.0 million and $145.5 million, respectively, on our interest rate swaps, compared to losses of $90.9 million and $106.8 million in the three and six months ended March 31, 2016, respectively. Of the total net gains, non-cash mark-to-market adjustments of $1.6 million and $146.6 million were recognized in the three and six months ended March 31, 2017, respectively, offset by $0.6 million and $1.1 million paid for cash settlements in the three and six months ended March 31, 2017, respectively. For the three and six months ended March 31, 2016, all losses were related to non-cash mark-to-market adjustments. For additional information on our interest rate swaps, refer to Note 11 within the Notes to Condensed Consolidated Financial Statements and Quantitative and Qualitative Disclosures About Market Risk within Item 3.

### Income Taxes

The effective income tax rate was 5% and 35% for the three and six months ended March 31, 2017, respectively, and 188% and 10% for the three and six months ended March 31, 2016, respectively. In accordance with Accounting Standards Codification (“ASC”) Topic 740, we record income tax expense for the interim periods using the estimated annual effective tax rate for the full fiscal year adjusted for the impact of discrete items occurring during the three and six month periods. In the three months ended March 31, 2017, the effective tax rate differed significantly from the statutory rate as a result of the expectation that the Domestic Production Activities Deduction under the Internal Revenue Code (“DPAD”) would have a favorable impact on the effective income tax rate, and that certain valuation allowances would have an unfavorable impact on the effective income tax rate. In the fiscal 2016 periods, the effective tax rate differed significantly from the statutory rate as a result of discrete items occurring in the second quarter of fiscal 2016 primarily relating to our decision to exit our Canadian egg business reported in the Michael Foods Group segment and the expectation that the DPAD would have a favorable impact on the effective income tax rate.

### SEGMENT RESULTS

Our reportable segments are as follows:

- Post Consumer Brands: primarily RTE cereals;
- Michael Foods Group: eggs, potatoes, cheese and pasta;
- Active Nutrition: protein shakes, bars and powders and nutritional supplements; and
- Private Brands: primarily peanut and other nut butters, dried fruit and nuts, and granola.

We evaluate each segment’s performance based on its segment profit, which is its operating profit before impairment of property and intangible assets, facility closure related costs, restructuring expenses, (gains)/losses on assets held for sale, gain on sale of plant and other unallocated corporate income and expenses.

### Post Consumer Brands

*dollars in millions*

|  | Three Months Ended March 31, 2017 | 2016 | favorable/(unfavorable) $ Change | % Change | Six Months Ended March 31, 2017 | 2016 | favorable/(unfavorable) $ Change | % Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Net Sales | $431.1 | $440.1 | $(9.0) | (2)% | $851.7 | $851.7 | $— | —% |
| Segment Profit | $90.1 | $74.7 | $15.4 | 21% | $171.7 | $137.6 | $34.1 | 25% |
| Segment Profit Margin | 21% | 17% |  |  | 20% | 16% |  |  |

Net sales for the Post Consumer Brands segment decreased $9.0 million, or 2%, for the three months ended March 31, 2017 as compared to the prior year period resulting from lower average net selling prices and reduced volumes. Average net selling prices decreased 1% during the three months ended March 31, 2017 primarily due to higher trade spending partially offset by a favorable sales mix as branded volumes increased and lower margin co-manufacturing and governmental bid business volumes decreased. The favorable shift in sales mix was driven by targeted promotional activity combined with intentional volume reductions in our governmental bid business. Overall volumes decreased 1%, primarily due to reductions in *Great Grains, Honey Bunches of Oats*, co-manufacturing, governmental bid business and adult classic brands, partially offset by a combined 7% increase in *Pebbles* and *Malt-O-Meal* branded products.

Net sales for the Post Consumer Brands segment were flat for the six months ended March 31, 2017 as compared to the prior year period with 1% higher average net selling prices being offset by 1% lower volumes. The increase in average net selling prices was driven by a favorable sales mix as branded volumes increased and lower margin co-manufacturing and governmental bid business volumes decreased. This increase was partially offset by higher trade spending. Volume decreases were primarily due to reductions in *Great Grains, Honey Bunches of Oats,* co-manufacturing, governmental bid business and adult classic brands, partially offset by a combined 7% increase in *Pebbles* and *Malt-O-Meal* branded products.

Segment profit for the three months ended March 31, 2017 increased $15.4 million, or 21%, when compared to the prior year. The increase in segment profit was primarily due to a 393 basis point improvement in segment profit margin. This improvement was driven by reduced advertising and promotional spending of $12.8 million, lower materials costs and $1.5 million lower integration costs in the three months ended March 31, 2017 as compared to the prior year. These increases were partially offset by higher manufacturing costs of $4.9 million and lower net sales, as previously discussed.

Segment profit for the six months ended March 31, 2017 increased $34.1 million, or 25%, when compared to the prior year. The increase in segment profit was primarily due to a 400 basis point improvement in segment profit margin. This improvement was driven by reduced advertising and promotional spending of $15.7 million, lower materials costs and $8.9 million lower integration costs in the six months ended March 31, 2017 as compared to the prior year. These increases were partially offset by higher manufacturing costs of $7.0 million.

### Michael Foods Group

*dollars in millions*

|  | Three Months Ended March 31, 2017 | 2016 | favorable/(unfavorable) $ Change | % Change | Six Months Ended March 31, 2017 | 2016 | favorable/(unfavorable) $ Change | % Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Net Sales | $515.0 | $557.7 | $(42.7) | (8)% | $1,054.8 | $1,144.1 | $(89.3) | (8)% |
| Segment Profit | $42.7 | $89.6 | $(46.9) | (52)% | $25.7 | $170.4 | $(144.7) | (85)% |
| Segment Profit Margin | 8% | 16% |  |  | 2% | 15% |  |  |

Net sales for the Michael Foods Group segment decreased $42.7 million, or 8%, for the three months ended March 31, 2017. Excluding the impact of the current year acquisition of NPE, net sales decreased $66.3 million, or 12%. Excluding the current year impact of NPE, egg product sales were down 11%, with volume up 2%. Volumes increased in the three months ended March 31, 2017 as egg supply returned to levels consistent with those prior to the spring 2015 outbreak of avian influenza (“AI”) which reduced our egg supply available for sale in the prior year. Despite higher volumes, revenues decreased due to lower selling prices resulting from the reversal of price increases taken in the prior year to offset higher costs incurred as a result of AI, as well as significantly lower market-based egg prices. Refrigerated potato products sales were up 4%, with volume up 6%. Pasta sales were down 12% on 5% lower volumes, primarily due to weather-related production issues and the pass through of lower wheat ingredient costs to customers. Cheese and other dairy case products sales were down 22%, with volume down 23%, primarily due to losses within the low-margin private label cheese business and branded cheese distribution losses and general demand weakness. Net sales for the Michael Foods Group were also impacted in the three months ended March 31, 2017 by the absence of sales from our Michael

Foods Canadian egg business ($3.4 million for the three months ended March 31, 2016) which was sold in the second quarter of fiscal 2016.

Net sales for the Michael Foods Group segment decreased $89.3 million, or 8%, for the six months ended March 31, 2017. Excluding the impact of the current year acquisition of NPE, net sales decreased $136.2 million, or 12%. Excluding the current year impact of NPE, egg product sales were down 12%, with volume up 6%. Volumes increased as egg supply returned to levels consistent with those prior to the outbreak of AI, and revenues decreased due to lower selling prices resulting from the reversal of price increases taken in the prior year to offset higher costs incurred as a result of AI, as well as significantly lower market-based egg prices. Refrigerated potato products sales were up 2%, with volume up 3%. Pasta sales were down 9% on 3% lower volumes, primarily due to weather-related production issues and the pass through of lower wheat ingredient costs to customers. Cheese and other dairy case products sales were down 21% on 21% lower volumes, primarily due to losses within the low-margin private label cheese business and branded cheese distribution losses and general demand weakness. Net sales for the Michael Foods Group were also impacted in the six months ended March 31, 2017 by the absence of sales from our Michael Foods Canadian egg business ($9.6 million for the six months ended March 31, 2016) which was sold in the second quarter of fiscal 2016.

Segment profit decreased $46.9 million, or 52%, for the three months ended March 31, 2017. Excluding the impact of the current year acquisition of NPE, segment profit decreased $46.3 million, or 52%. Egg results decreased as a result of lower net selling prices, as previously discussed. Cheese and dairy results decreased $5.1 million as a result of lost volume, as previously discussed. Pasta results were down year over year driven by lower volumes and higher manufacturing costs. These decreases were partially offset by favorable potato results compared to the prior year.

Segment profit decreased $144.7 million, or 85%, for the six months ended March 31, 2017. Excluding the impact of the current year acquisition of NPE, segment profit decreased $142.0 million, or 83%. The decrease in segment profit is primarily due to provisions for legal settlements of $74.5 in the first quarter of 2017. In addition, egg results decreased compared to fiscal 2016, due to lower net selling prices, as previously discussed. Cheese and dairy results decreased $5.7 million as a result of lost volume, as previously discussed. Pasta results were down year over year driven by lower volumes and higher manufacturing costs. These decreases were partially offset by favorable potato results compared to the prior year.

### Active Nutrition

*dollars in millions*

|  | Three Months Ended March 31, 2017 | 2016 | favorable/(unfavorable) $ Change | % Change | Six Months Ended March 31, 2017 | 2016 | favorable/(unfavorable) $ Change | % Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Net Sales | $177.3 | $143.8 | $33.5 | 23% | $331.2 | $259.6 | $71.6 | 28% |
| Segment Profit | $21.2 | $13.8 | $7.4 | 54% | $46.1 | $24.3 | $21.8 | 90% |
| Segment Profit Margin | 12% | 10% |  |  | 14% | 9% |  |  |

Net sales for the Active Nutrition segment increased $33.5 million, or 23%, for the three months ended March 31, 2017, primarily attributable to protein shake and other RTD sales, where gross sales were up 51% on 51% higher volumes, fueled by increased consumption and distribution of shakes, as well as new product introductions. Gross sales for bars were up 4% on 2% lower volumes and gross sales for powders were up 3% on 10% higher volumes. Average net selling prices for the Active Nutrition segment were down primarily due to higher trade spending in the three months ended March 31, 2017.

Net sales for the Active Nutrition segment increased $71.6 million, or 28%, for the six months ended March 31, 2017, primarily attributable to protein shake and other RTD sales, where gross sales were up 57% on 55% higher volumes, fueled by increased consumption and distribution of shakes, as well as new product introductions. Gross sales for bars were up 5% on 4% higher volumes and gross sales for powders were up 2% on 10% higher volumes. Average net selling prices for the Active Nutrition segment were down primarily due to higher trade spending in the six months ended March 31, 2017.

Segment profit increased $7.4 million, or 54%, for the three months ended March 31, 2017. This increase was driven by higher volumes, as previously described, and favorable raw material costs of $8.3 million, partially offset by $6.3 million higher advertising and promotion spending.

Segment profit increased $21.8 million, or 90%, for the six months ended March 31, 2017. This increase was driven by higher volumes, as previously described, and favorable raw material costs of $13.9 million, partially offset by $8.5 million higher advertising and promotion spending and increased employee-related expenses resulting from increased headcount to support the growing segment.

### Private Brands

*dollars in millions*

|  | Three Months Ended March 31, 2017 | 2016 | favorable/(unfavorable) $ Change | % Change | Six Months Ended March 31, 2017 | 2016 | favorable/(unfavorable) $ Change | % Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Net Sales | $132.1 | $129.7 | $2.4 | 2% | $267.7 | $265.3 | $2.4 | 1% |
| Segment Profit | $9.5 | $7.7 | $1.8 | 23% | $16.5 | $20.6 | $(4.1) | (20)% |
| Segment Profit Margin | 7% | 6% |  |  | 6% | 8% |  |  |

Net sales for the Private Brands segment increased $2.4 million, or 2%, for the three months ended March 31, 2017 (including reduced intercompany sales of $0.1 million to the Post Consumer Brands segment). Net sales were positively impacted by a favorable sales mix with increases in higher-margin organic peanut butter and tree nut butters, as well as an increase in traditional peanut butter sales. Overall volumes were flat as these increases along with increases in cereal were offset by declines in dried fruit and nut and granola. Net selling prices were lower in the three months ended March 31, 2017, as raw material cost savings were passed through to customers and trade spending related to branded products increased.

Net sales for the Private Brands segment increased $2.4 million, or 1%, for the six months ended March 31, 2017 (including reduced intercompany sales of $0.6 million to the Post Consumer Brands segment). Net sales were positively impacted by a favorable sales mix with a shift towards higher-margin organic peanut butter and away from lower-margin traditional peanut butter sales. This mix improvement was partially offset by overall segment volume declines of 1% and lower net selling prices resulting from raw material cost savings being passed through to customers as well as higher trade spending on branded products.Volume declines are primarily attributable to lower traditional peanut butter and dried fruit and nut volumes, partially offset by higher organic peanut butter, tree-nut butters, cereal and granola volumes.

Segment profit increased $1.8 million, or 23%, for the three months ended March 31, 2017 due to a favorable sales mix, as previously discussed, lower raw material costs and favorable foreign exchange conversion rates. These increases were partially offset by increased expenses related to co-manufacturing agreements and higher manufacturing costs resulting from capacity constraints. Segment profit in the three months ended March 31, 2016 was negatively impacted by losses of $0.6 million on a disposal of fixed assets.

Segment profit decreased $4.1 million, or 20%, for the six months ended March 31, 2017 primarily due to lower volumes, as previously discussed, increased expenses related to co-manufacturing agreements and higher manufacturing costs resulting from capacity constraints. These decreases were partially offset by a favorable sales mix, as previously discussed, and favorable foreign exchange conversion rates. Segment profit in the six months ended March 31, 2016 was negatively impacted by losses of $0.6 million on a disposal of fixed assets.

### General Corporate Expenses and Other

*dollars in millions*

|  | Three Months Ended March 31, 2017 | 2016 | favorable/(unfavorable) $ Change | % Change | Six Months Ended March 31, 2017 | 2016 | favorable/(unfavorable) $ Change | % Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| General corporate expenses and other | $26.0 | $23.3 | $(2.7) | (12)% | $46.3 | $57.5 | $11.2 | 19% |

General corporate expenses and other increased $2.7 million, or 12%, during the three months ended March 31, 2017. The increase was due to higher third party acquisition and divestiture related costs of $2.6 million, increased losses (as compared to gains in the prior year) related to mark-to-market adjustments on commodity hedges of $4.1 million and higher stock-based compensation of $1.8 million. These increases were partially offset by lower restructuring and plant closure costs of $0.8 million and lower outside professional services costs of $1.3 million. In addition, losses on assets held for sale of $4.4 million were recorded in the three months ended March 31, 2016 to adjust the carrying value of the assets to their final fair value less estimated selling costs.

General corporate expenses and other decreased $11.2 million, or 19%, during the six months ended March 31, 2017. The decrease was due to lower restructuring and plant closure costs of $5.1 million, increased gains (as compared to losses in the prior year) related to mark-to-market adjustments on commodity hedges of $1.2 million and lower outside professional services costs of $3.4 million. In addition, a gain on assets held for sale of $0.2 million was recorded in the six months ended March 31, 2017 to adjust the carrying value of the assets to their final fair value less estimated selling costs compared to losses on assets held for sale of $8.4 million in the prior year. These decreases were partially offset by higher stock-based compensation of $3.7 million and increased third party acquisition and divestiture related costs of $1.3 million.

#### Restructuring and Plant Closure

The table below shows the amount of restructuring and plant closure costs attributable to each segment. These amounts are excluded from the measure of segment profit but are included in “General corporate expenses and other.” For additional information on our restructuring and plant closure costs, refer to Note 3 in the “Notes to Consolidated Financial Statements.”

*dollars in millions*

|  | Three Months Ended March 31, 2017 | 2016 | $ Change | Six Months Ended March 31, 2017 | 2016 | $ Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Post Consumer Brands | $— | $0.3 | $0.3 | $— | $0.8 | $0.8 |
| Active Nutrition | — | 0.5 | 0.5 | 0.2 | 4.5 | 4.3 |
|  | $— | $0.8 | $0.8 | $0.2 | $5.3 | $5.1 |

#### Assets Held for Sale

The table below shows the amount of (gain) losses on assets held for sale attributable to each segment. These amounts are excluded from the measure of segment profit but are included in “General corporate expenses and other.” For additional information on our assets held for sale, refer to Note 3 and Note 12 in the “Notes to Consolidated Financial Statements.”

*dollars in millions*

|  | Three Months Ended March 31, 2017 | 2016 | $ Change | Six Months Ended March 31, 2017 | 2016 | $ Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Post Consumer Brands | $— | $1.4 | $1.4 | $— | $5.0 | $5.0 |
| Active Nutrition | — | 3.0 | 3.0 | (0.2) | 3.4 | 3.6 |
|  | $— | $4.4 | $4.4 | $(0.2) | $8.4 | $8.6 |

### LIQUIDITY AND CAPITAL RESOURCES

During the first quarter of fiscal 2017, we repurchased 1.7 million shares of our common stock at an average share price of$76.32 for a total cost of $133.1 million.

In February 2017, we issued 5.50% and 5.75% senior notes due in March 2025 and March 2027, respectively, in an aggregate principal amount of $1,750.0 million. The majority of the proceeds were used to repay the 7.375% and 6.75% senior notes maturing February 2022 and December 2021, respectively, with a total principal value of approximately $1,008.0 million.

In March 2017, we amended and restated our existing credit agreement (as amended and restated, the “Credit Agreement”). The Credit Agreement provides for a revolving credit facility in an aggregate principal amount of $800.0 million.

In April 2017, we announced an agreement to acquire the *Weetabix* brand and all of the issued share capital of Latimer Newco 2 Limited (“Weetabix”) for approximately £1,400.0, on a cash-free, debt-free basis, subject to certain adjustments as described in the purchase agreement. The acquisition is expected to close in the third quarter of calendar 2017, or our fourth fiscal quarter.

In May 2017, we announced the commencement of cash tender offers (the “Tender Offers”) to purchase any and all of our 7.75% senior notes, having an aggregate outstanding principal amount of $800.0 million and any and all of our 8.00% senior notes, having an aggregate outstanding principal amount of $400.0 million. We also announced that we intend to borrow approximately $2.0 billion under a new incremental term loan facility under our existing credit facility, which, in part, along with cash on hand, will be used to fund the Tender Offers as well as the acquisition of Weetabix.

The following table shows select cash flow data, which is discussed below.

*dollars in millions*

|  | Six Months Ended March 31, 2017 | 2016 |
| --- | ---: | ---: |
| Cash (used in) provided by operating activities | $(26.5) | $196.4 |
| Cash used in investing activities | (141.6) | (122.0) |
| Cash provided by (used in) financing activities | 509.8 | (48.5) |
| Effect of exchange rate changes on cash | (0.4) | 0.9 |
| Net increase in cash and cash equivalents | $341.3 | $26.8 |

Historically, we have generated and expect to continue to generate positive cash flows from operations. We believe our cash on hand, cash flows from operations and our current and possible future credit facilities will be sufficient to satisfy our future working capital requirements, interest payments, research and development activities, capital expenditures, pension contributions and other financing requirements for the foreseeable future. Our ability to generate positive cash flows from operations is dependent on general economic conditions, competitive pressures and other business risk factors. If we are unable to generate sufficient cash flows from operations, or otherwise to comply with the terms of our credit facilities, we may be required to seek additional financing alternatives or waivers under our Credit Agreement and indentures governing our senior notes in order to generate additional cash. There can be no assurance that we would be able to obtain additional financing or any such waivers on terms acceptable to us or at all. For additional information on our debt, refer to Note 14 within the Notes to Condensed Consolidated Financial Statements.

Short-term financing needs primarily consist of working capital requirements, principal and interest payments on our long-term debt and dividend payments on our cumulative preferred stock. Long-term financing needs will depend largely on potential growth opportunities, including acquisition activity and repayment or refinancing of our long-term debt obligations.

Cash used in operating activities for the six months ended March 31, 2017 was $26.5 million compared to cash provided by operating activities of $196.4 million in the prior year period. The year over year change was primarily driven by $103.0 million of legal settlements paid in the current year period, increased payments of advertising and promotional expenses in the current year, increased incentive payments paid in the current year on above target fiscal 2016 performance and higher interest payments of $5.6 million. Working capital was also impacted in the six months ended March 31, 2017 by an increase in income taxes receivable of $48.0 million which included lower payments for income taxes of $19.9 million in the current year as compared to the six months ended March 31, 2016.

Cash used in investing activities for the six months ended March 31, 2017 increased $19.6 million compared to the prior year period, driven by an increase in capital expenditures of $19.1 million and net proceeds received from the sale of businesses of $6.2 million in the prior year partially offset by a reduction in cash paid for acquisitions of $4.2 million and $10.3 million of proceeds received from the sale of our Modesto and Farmers Branch facilities.

Cash provided by financing activities for the six months ended March 31, 2017 was $509.8 million compared to cash used in financing activities of $48.5 million in the prior year period. In the second quarter of fiscal 2017, we completed a debt refinancing in which we issued $1,750.0 million principal of 5.50% and 5.75% senior notes and utilized a portion of the proceeds to repay the outstanding principal balances of our 7.375% and 6.75% senior notes, which resulted in a total principal payment of $1,008.0 million. Related to the refinancing, we paid a tender premium of $67.9 million for the early extinguishment of the senior notes. For the issuance of the new senior notes and the amendment and restatement of our Credit Agreement, we paid $27.6 million in debt issuance costs and deferred financing fees. During the first quarter of fiscal 2017, we also repurchased 1.7 million shares of our common stock at a cost of $133.1 million. The prior year outflow was driven by $28.3 million net cash paid in advance for stock repurchase contracts and a $10.9 million payment related to the December 2015 conversion of 0.9 million shares of our 3.75% Series B Cumulative Perpetual Convertible Preferred Stock.

### Debt Covenants

Under the terms of the Credit Agreement, we are required to comply with a financial covenant consisting of a ratio for quarterly maximum senior secured leverage if all outstanding amounts under the revolving credit facility exceed 30% of the Company’s revolving credit commitments. As of March 31, 2017, we were in compliance with such financial covenant. We do not believe non-compliance is reasonably likely in the foreseeable future.

Our Credit Agreement permits us to incur additional unsecured debt if, among other conditions, our pro forma consolidated interest coverage ratio, calculated as provided in the Credit Agreement, would be greater than or equal to 2.00 to 1.00 after giving effect to such new debt. As of March 31, 2017, our pro forma consolidated interest coverage ratio exceeded this threshold.

### CRITICAL ACCOUNTING POLICIES AND ESTIMATES

The following discussion is presented pursuant to the United States Securities and Exchange Commission’s Financial Reporting Release No. 60, “Cautionary Advice Regarding Disclosure About Critical Accounting Policies.” The policies below are both important to the presentation of Post’s financial condition and results and require management’s most difficult, subjective or complex judgments.

Under generally accepted accounting principles in the United States, we make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues, and expenses as well as the disclosure of contingent liabilities. We base estimates on past experience and on various other assumptions that are believed to be reasonable under the circumstances. Those estimates form the basis for making judgments about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

Our critical accounting policies and estimates are more fully described in our Annual Report on Form 10-K for the year ended September 30, 2016 as filed with the SEC on November 18, 2016. There have been no significant changes to our critical accounting policies and estimates since September 30, 2016.

As discussed in greater detail in our Annual Report on Form 10-K for the year ended September 30, 2016, our Dymatize reporting unit, which is included in our Active Nutrition segment, failed the first step of the goodwill impairment test but was ultimately not impaired in fiscal 2016. During the first six months of fiscal 2017, the specialty sports nutrition channel, in which Dymatize sells the majority of its products, has continued to experience weaker than anticipated sales. If the specialty channel declines continue or accelerate and we are unsuccessful in moving into alternative channels, management will have to reassess its long-term expectations for the Dymatize reporting unit. This reassessment could ultimately result in impairments within our Active Nutrition segment, which could be material to our financial statements. We will continue to monitor our actual performance and overall category trends against our long-range estimates.

### RECENTLY ISSUED ACCOUNTING STANDARDS

See Note 2 of “Notes to Consolidated Financial Statements” for a discussion regarding recently issued accounting standards.

### CAUTIONARY STATEMENTS REGARDING FORWARD-LOOKING STATEMENTS

Forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), are made throughout this report. These forward-looking statements are sometimes identified by the use of terms and phrases such as “believe,” “should,” “expect,” “project,” “estimate,” “anticipate,” “aim,” “intend,” “plan,” “will,” “can,” “may,” or similar expressions elsewhere in this report. Our results of operations and financial condition may differ materially from those in the forward-looking statements. Such statements are based on management’s current views and assumptions, and involve risks and uncertainties that could affect expected results. Those risks and uncertainties include but are not limited to the following:

- the timing to consummate the pending acquisition of Weetabix;
- the ability and timing to obtain required regulatory approvals and satisfy other closing conditions;
- our ability to promptly and effectively integrate the Weetabix business and obtain expected cost savings and synergies within the expected timeframe;
- operating costs, customer loss and business disruption (including, without limitation, difficulties in maintaining relationships with Weetabix employees, customers or suppliers) that may be greater than expected following the consummation of the acquisition of Weetabix;
- our ability to retain certain key employees at Weetabix;
- our ability to borrow funds under a new senior secured term loan facility on terms acceptable to us or at all;
- the risks associated with the disruption of management’s attention from ongoing business operations due to the Weetabix transaction;
- our ability to continue to compete in our product markets and our ability to retain our market position;
- our ability to anticipate and respond to changes in consumer preferences and trends;
- our ability to identify and complete acquisitions and manage our growth;
- changes in our cost structure, management, financing and business operations;
- our ability to integrate acquired businesses and whether acquired businesses will perform as expected;
- changes in economic conditions and consumer demand for our products;
- significant volatility in the costs of certain raw materials, commodities, packaging or energy used to manufacture our products;
- impairment in the carrying value of goodwill or other intangibles;
- our ability to successfully implement business strategies to reduce costs;
- our ability to comply with increased regulatory scrutiny related to certain of our products and/or international sales;
- allegations that our products cause injury or illness, product recalls and product liability claims and other litigation;
- legal and regulatory factors, including environmental laws, advertising and labeling laws, changes in food safety and laws and regulations governing animal feeding and housing operations;
- our ability to maintain competitive pricing, introduce new products and successfully manage our costs;
- the ultimate impact litigation may have on us;
- the ultimate outcome of the remaining portions of the Michael Foods egg antitrust litigation, including formal court approval of the announced settlement with the direct purchaser plaintiffs;
- the loss or bankruptcy of a significant customer;
- consolidations in the retail grocery and foodservice industries;
- the ability of our private label products to compete with nationally branded products;
- disruptions or inefficiencies in supply chain;
- our reliance on third party manufacturers for certain of our products;
- disruptions in the U.S. and global capital and credit markets;
- fluctuations in foreign currency exchange rates;
- changes in estimates in critical accounting judgments and changes to or new laws and regulations affecting our business;
- loss of key employees;
- changes in weather conditions, natural disasters, disease outbreaks and other events beyond our control;
- labor strikes, work stoppages or unionization efforts;
- losses or increased funding and expenses related to our qualified pension and other post-retirement plans;
- business disruptions caused by information technology failures and/or technology hacking;
- our ability to protect our intellectual property;
- media campaigns and improper use of social media that damage our brands;
- our ability to successfully operate our international operations in compliance with applicable laws and regulations;
- significant differences in our actual operating results from our guidance regarding our future performance;
- our ability to satisfy the requirements of Section 404 of the Sarbanes-Oxley Act of 2002, including with respect to acquired businesses;
- our high leverage and substantial debt, including covenants that restrict the operation of our business;
- our ability to service our outstanding debt or obtain additional financing, including both secured and unsecured debt; and
- other risks and uncertainties included under “Risk Factors” in this document, in our Annual Report on Form 10-K for the fiscal year ended September 30, 2016, filed with the SEC on November 18, 2016, and in our Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2016, filed with the SEC on February 3, 2017.

You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this document to conform these statements to actual results or to changes in our expectations.

## Market risk

As filed, 2,140 characters.

### Interest Rate Risk

As of March 31, 2017, we had outstanding principal value of indebtedness of $5,334.7 million related to our various senior notes issuances, our 5.25% tangible equity units, remaining principal balance for debt assumed in the acquisition of Michael Foods and National Pasteurized Eggs, Inc. and a revolving credit facility with a $800.0 million borrowing capacity. The revolving credit facility has outstanding letters of credit of $10.0 million which reduced the available borrowing capacity to $790.0 million at March 31, 2017. The total $5,334.7 million outstanding indebtedness bears interest at fixed rates with a weighted-average interest rate of 6.0% and is not subject to change based on changes in market interest rates.

As of March 31, 2017, we had interest rate swaps with a notional amount of $76.8 million that obligate us to pay a fixed rate of 3.1% and receive one-month LIBOR. Cash settlements on these swaps began in July 2016 and will end in May 2021. In addition, we have interest rate swaps with a $750.0 million notional amount that obligate us to pay a weighted-average fixed rate of approximately 4.0% and receive three-month LIBOR and will result in a lump sum net settlement in July 2018, as well as interest rate swaps with a $899.3 million notional amount that obligate us to pay a weighted-average fixed rate of approximately 3.7% and receive three-month LIBOR and will result in a lump sum net settlement in December 2019.

Borrowings under the revolving credit facility will bear interest, at our option, at an annual rate equal to either the Base Rate, Eurodollar Rate or Canadian Dollar Offered Rate (“CDOR Rate”) plus an applicable margin ranging from 1.75% to 2.25% for

Eurodollar Rate-based loans and CDOR Rate-based loans and from 0.75% to 1.25% for Base Rate-based loans, depending in each case on our senior secured leverage ratio.

There have been no material changes in our assessment of market risk sensitivity since our presentation of “Quantitative and Qualitative Disclosures About Market Risk” in our Annual Report on Form 10-K, as filed with the SEC on November 18, 2016.

## Controls and procedures

As filed, 1,439 characters.

#### Evaluation of Disclosure Controls and Procedures

Our management, with the Chief Executive Officer (CEO) and Chief Financial Officer (CFO) of the Company, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this report. Based on that evaluation, our CEO and CFO concluded that, as of the end of the period covered by this report, the Company’s disclosure controls and procedures were effective to provide reasonable assurance of achieving the desired control objectives.

#### Changes in Internal Control Over Financial Reporting

In connection with the Company’s acquisitions in fiscal 2016 and 2017, management is in the process of analyzing, evaluating and, where necessary, implementing changes in controls and procedures. This process may result in additions or changes to the Company’s internal control over financial reporting. The Company’s fiscal 2017 acquisition of National Pasteurized Eggs, Inc. will be excluded from management's assessment of internal control over financial reporting as of September 30, 2017.

Except as noted above, there were no changes in the Company’s internal control over financial reporting during the quarter ended March 31, 2017 that may have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

## Risk factors

As filed, 10,563 characters.

In addition to the information set forth below and elsewhere in this Form 10-Q, you should carefully consider the risk factors we previously disclosed in our Annual Report on Form 10-K, filed with the SEC on November 18, 2016, as of and for the year ended September 30, 2016, and in our Quarterly Report on Form 10-Q, filed with the SEC on February 3, 2017, in addition to those risk factors set forth below. These risks could materially and adversely affect our business, financial condition and results of operations. These enumerated risks are not the only risks we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations, financial condition or results.

***Our pending acquisition of Weetabix may not be consummated, and if the transaction is not completed, we may be subject to monetary or other damages under the purchase agreement.***

On April 18, 2017, we entered into a purchase agreement to acquire all of the equity of Latimer Newco 2 Limited (“Weetabix”) for approximately £1.4 billion on a cash-free, debt-free basis, subject to certain adjustments as described in the purchase agreement. Completion of this acquisition is subject to certain limited closing conditions, including regulatory review as described below.

We expect the transaction to close in the third quarter of 2017 (our fiscal fourth quarter). There can be no assurance, however, that all closing conditions for the acquisition will be satisfied and, if they are satisfied, that they will be satisfied in time for the closing to occur during the period noted above. The purchase agreement may be terminated under certain limited circumstances, and the purchase agreement automatically terminates if the limited closing conditions have not been satisfied or waived by December 27, 2017.

If the limited closing conditions have not been satisfied because, on or before December 27, 2017, expiration of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the “HSR Act”) has not occurred and/or applicable approvals from the Competition Authority of Kenya have not been received, other than as a result of the sellers not complying with their obligations relating to such closing conditions, and all other closing conditions have been satisfied or waived by the Company, then the Company must pay to the sellers a termination fee of £30.0 million.

We intend to finance a portion of the purchase price with debt financing. However, our ability to obtain financing is not a condition to closing under the purchase agreement. We believe that the new proceeds of any financing we obtain, together with cash on hand, will be sufficient to fund the purchase price for the Weetabix acquisition. However, our ability to obtain financing may be subject to certain conditions that may not be satisfied at the closing of the acquisition. If we are unable to obtain sufficient financing or experience a significant diminution of our existing cash and cash equivalents or other sources of capital, and as a result we do not have sufficient funds to complete the acquisition of Weetabix, we may be subject to monetary or other damages under the purchase agreement as a result of our failure to complete the acquisition.

***Failure to complete the Weetabix acquisition could impact our stock price, our future business and financial results and/or our operations.***

If the acquisition of Weetabix is not completed, our ongoing business and financial results may be adversely affected and we will be subject to a number of risks, including the following:

- depending on the reasons for the failure to complete the Weetabix acquisition, we could be liable to the sellers for monetary or other damages in connection with the termination or breach of the purchase agreement;
- we have dedicated significant time and resources, financial and otherwise, in planning for the acquisition and the associated integration;
- we are responsible for certain transaction costs relating to the Weetabix acquisition, whether or not the acquisition is completed;
- while the purchase agreement is in force, we are subject to certain restrictions, including our ability to pursue other acquisitions that could reasonably be expected to prejudice or delay the receipt of the U.S. or Kenyan regulatory clearances required to complete the Weetabix acquisition, which may adversely affect our ability to execute certain of our business strategies; and
- matters relating to the acquisition (including integration planning) may require substantial commitments of time and resources by our management, whether or not the acquisition is completed, which could otherwise have been devoted to other opportunities that may have been beneficial to us.

In addition, if the Weetabix acquisition is not completed, we may experience negative reactions from the financial markets and from our customers and employees. We may also be subject to litigation related to any failure to complete the acquisition or to enforcement proceedings commenced against us to perform our obligations under the purchase agreement. If the acquisition is not completed, these risks may materialize and may adversely affect our business, financial results and financial condition, as well as the price of our common stock.

***We may be unable to integrate the Weetabix business successfully and realize the anticipated benefits of the acquisition.***

The acquisition of Weetabix involves the combination of two companies that currently operate independently. We will be required to devote significant management attention and resources to integrating business practices, cultures and operations of each business, in particular our Post Consumer Brands business and Weetabix’s North American business operations. Potential difficulties we may encounter as part of the integration process include the following:

- the inability to successfully combine our business with that of Weetabix in a manner that permits us to achieve the synergies and other benefits anticipated to result from the acquisition;
- the challenge of integrating complex systems, operating procedures, regulatory compliance programs, technology, networks and other assets of Weetabix in a seamless manner that minimizes any adverse impact on customers, suppliers, employees and other constituencies;
- potential unknown liabilities, liabilities that are significantly larger than we currently anticipate and unforeseen increased expenses or delays associated with the acquisition, including cash costs to integrate the two businesses that may exceed the cash costs that we currently anticipate; and
- although the warranties regarding the business and operations of Weetabix made by certain of the sellers who are members of Weetabix’s management in the management warranty deed executed simultaneously with the purchase agreement survive the closing and we have indemnification rights against these members of management in the event any of such warranties prove after the closing to have been inaccurate or breached, the liability of these members of management for such claims is capped at £2.2 million in the aggregate, and no portion of the purchase price for the transaction will be held in escrow for the purpose of funding indemnification claims under the management warranty deed, so we may not be able to collect any damages we may incur for inaccuracies or breaches in warranties from these members of management after closing.

Accordingly, even if the acquisition of Weetabix is consummated, the contemplated benefits may not be realized fully, or at all, or may take longer to realize than expected.

***We may be unable to obtain the regulatory clearances required to complete the Weetabix acquisition or, in order to do so, we or Weetabix may be required to comply with material restrictions or satisfy material conditions.***

The closing of the acquisition is subject to the condition that the applicable waiting period, including any applicable extension thereof, under the HSR Act has expired or been duly terminated and that the applicable approvals from the Competition Authority of Kenya have been received (and in the event that Kenyan approval is delayed under certain circumstances set forth in the purchase agreement, the Kenyan antitrust condition will be deemed satisfied provided that the shares in Weetabix’s Kenyan entity remain with the sellers until such time as the Kenyan approval is received). We cannot provide any assurance that all required regulatory clearances will be obtained. If a governmental authority asserts objections to the acquisition, we may be required to divest some assets or take other action in order to obtain antitrust clearance. There can be no assurance as to the cost, scope or impact of the actions that may be required to obtain antitrust or other regulatory approval. In addition, the purchase agreement provides that we are subject to certain covenants to obtain antitrust clearance, such that if a governmental authority asserts objections to the acquisition, we may be required to divest some assets or take other action in order to obtain antitrust clearance. If we are required to take such actions in order to close the acquisition, it could be detrimental to the combined organization following the consummation of the acquisition. Furthermore, these actions could have the effect of delaying or preventing completion of the proposed acquisition or imposing additional costs on or limiting the revenues or cash of the combined organization following the consummation of the acquisition.

Even if the parties receive early termination of the statutory waiting period under the HSR Act or the waiting period required expires, the U.S. Department of Justice, the U.S. Federal Trade Commission, or other regulatory authorities could take action under the antitrust laws to prevent or rescind the acquisition, require the divestiture of assets or seek other remedies. Additionally, state attorneys general could seek to block or challenge the Weetabix acquisition as they deem necessary or desirable in the public interest at any time, including after completion of the transaction. In addition, in some circumstances, a third party could initiate a private action under antitrust laws challenging or seeking to enjoin the acquisition, before or after it is completed. We may not prevail and may incur significant costs in defending or settling any action under antitrust laws.

Filed May 9, 2017.
Source: SEC EDGAR, the filing index for accession 0001530950-17-000097. Last ingested by Listed: Nov 15, 2026, 00:14 ET. No prices; not investment advice.
